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Abstract
Moyamoya disease (MMD) is a rare disease affecting the cerebral vasculature 
of the central nervous system (CNS) with a reported incidence of 0.35–0.94 per 
100,000 populations. It was first reported from Japan and later from other parts of 
the world. The pathology is narrowing of blood vessels supplying anterior circula-
tion and rarely posterior circulation. It was believed that the disease is genetic in 
origin, but environmental factors also play a role. Patients with this rare disease 
may present with ischemic or hemorrhagic symptoms. Ischemic symptoms account 
for the disease in most of the pediatric patients, whereas in adults, hemorrhage is 
more common. Diagnostic imaging like CT angiogram and magnetic resonance 
angiogram helps in demonstrating the narrowing or the collateral vessels like “a 
puff of smoke” (moyamoya) formed at the base of the brain. Moyamoya disease is 
treated medically and/or surgically. Aspirin is the main medication used. Surgical 
options are direct or indirect revascularization techniques to bypass the stenosis. 
The disease is progressive in majority of the patients, but if treated early, they can 
have good prognosis especially children.
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1. Introduction
Moyamoya disease (MMD) is a rare disease of the central nervous system 
(CNS). It was first reported in Japan in the year 1957 and later reported from other 
Asian countries. “Moyamoya” in Japanese means “a puff of smoke” alluding to the 
characteristic angiographic appearance of the collateral circulation in the brain of 
the patient with moyamoya disease [1]. It can present either as an isolated condition 
(moyamoya disease) or as a part of a syndrome associated with other conditions. In 
the latter case, it is called moyamoya syndrome (MMS). Moyamoya disease usually 
manifests bilaterally [2], and moyamoya syndrome manifests, unilaterally, to begin 
with, which may progress to become bilateral disease [3].
2. Etiology
Ten to fifteen percent of moyamoya disease (MMD) is familial in origin which indi-
cates a genetic association. East Asian populations with RNF213 gene on chromosome 
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17q25.3 are susceptible to MMD [4]. In another report from Japan, it was observed that 
a variant of RNF213 (c.14576G) was present in 41 patients with familial MMD (95%), 
163 patients with sporadic MMD (79%), and 283 normal control subjects (2%) [5]. In 
a study in Chinese Han population, Wu et al. demonstrated that mutations in RNF213 
gene were associated with increased susceptibility to MMD. In further analysis, they 
observed that ischemic MMD was related to the R4810K mutation, and hemorrhagic 
MMD was associated with the A4399T mutation [6]. Mineharu et al. suggested that 
MMD is an autosomal dominant disease with incomplete penetrance [7]. Inoue et al. 
observed that different alleles of genes of HLA antigen have been found to be associ-
ated with MMD [8]. Several inducers of angiogenesis such as fibroblast growth factor, 
transforming growth factor beta1, and hepatocyte growth factor which promote 
neovascularization were found in high levels in patients with MMD [9–11].
Moyamoya syndrome (MMS) is a different entity when the disease is associated 
with some other conditions such as [12]:
1. Atherosclerosis
2. Infectious diseases: meningitis and other viral or bacterial infections
3. Hematologic conditions: sickle cell disease, beta thalassemia, Fanconi anemia, 
hereditary spherocytosis, homocystinuria and hyper-homocysteinemia, factor 
XII deficiency, essential thrombocythemia
4. Vasculitis and autoimmune diseases: systemic lupus erythematosus, pol-
yarteritis nodosa postinfectious vasculopathy, Graves’ disease thyroiditis, 
Sneddon syndrome, antiphospholipid antibody syndrome, anti-Ro and anti-La 
antibodies
5. Type 1 diabetes mellitus
6. Connective tissue disorders and neurocutaneous syndromes: neurofibroma-
tosis type 1 (NF1), tuberous sclerosis, Sturge-Weber syndrome, phakomatosis 
pigmentovascularis type IIIb, hypomelanosis of Ito, pseudoxanthoma elasti-
cum, Marfan syndrome, chromosomal disorders
7. Chromosomal disorders: down syndrome, turner syndrome, Alagille 
syndrome
8. Other vasculopathies: vasospasm after subarachnoid hemorrhage, radiation 
therapy to the base of the brain, fibromuscular dysplasia
9. Other extracranial cardiovascular diseases: congenital heart disease, Williams 
syndrome, coarctation of the aorta, renal artery stenosis
10. Metabolic diseases: type I glycogenosis, hyperphosphatasia, primary oxalosis
11. Cranial trauma
12. Brain tumors
13. Cavernous malformation
14. Pulmonary sarcoidosis
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15. Hereditary multisystem disorder with short stature, hypergonadotropic 
hypogonadism, and dysmorphism
16. Polycystic kidney disease
There are reports of identical twins with only one among them affected by 
MMD, which question the genetic basis and focus on environmental factors for the 
condition [13].
3. Epidemiology
Although originally reported in the Asian population, moyamoya disease has 
also been reported from Europe and America [1].
In an epidemiological study by Baba et al. [14], MMD was found to have the 
following characteristics in the Japanese population:
• Annual incidence of 0.35–0.94 per 100,000 populations
• A prevalence of 3.2–10.5 per 100,000 populations
• A male-to-female ratio of 1:1.8–1:2.2 reflecting a female predilection
• A family history of MMS in 10.0–15.4% of patients
Although the reported incidence of MMS from Washington and California was 
as low as 0.086 per 100,000 populations generally, in ethnic groups, it was found to 
be as high as 0.28 per 10,000 populations close to the incidence in Japan [15].
MMS shows a bimodal distribution in the Chinese population with a major peak 
in the 5–9-year-old group and another peak in the 35–39-year-old group [16]. In 
the Japanese population, there are two conflicting reports of higher peaks, one in 
childhood and another in adults [14, 17].
4. Clinical presentation
Patients affected by MMD present with ischemia like transient ischemic attack 
(TIA) and stroke and seizures or with intraparenchymal bleeds due to the rupture 
of fragile collateral vessels formed to compensate for the ischemia. They may also 
present with headache due to dilated transdural collateral blood vessels. A 2012 
systematic review of population-based studies by Kleinloog et al. found that the 
predominant mode of presentation was ischemia, especially in children [18]. 
Ninety percent of children present with stroke and 7.5% present with TIA as per 
International Pediatric Stroke Study published in 2017 [19]. In children, exercise, 
crying, coughing, straining, fever, or hyperventilation can trigger symptomatic 
episodes of ischemia.
Adult patients in Japan with MMS mostly present with hemorrhagic stroke in 
some old reports [20] in contrast to patients from the United States in whom the 
ischemic stroke was found to be more common [21]. In a study done on 88 Korean 
patients, 45% of them had only a single ischemic or hemorrhagic stroke, 55% recur-
rent attacks mostly ischemic, and 64% of them presented with hemiplegia [22].
Ischemic symptoms of MMD are typically associated with the anterior circula-
tion regions like frontal, parietal, and temporal lobes supplied by internal carotid 
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(ICA) and middle cerebral artery (MCA). Commonly the symptoms are hemipare-
sis, dysarthria, aphasia, and cognitive impairment [23]. Some patients may present 
with seizures, defective vision, syncopal attacks, or personality changes and can 
mimic psychiatric disorders [24]. Surgical patients undergoing minor procedures 
under anesthesia may present with perioperative stroke due to hyperventilation-
induced cerebral vasoconstriction of the already compromised cerebral vasculature 
of the ischemic penumbra [25]. Patients with MMD can develop cerebral aneurysms 
at the tip of the basilar artery and the posterior communicating artery and present 
with subarachnoid hemorrhage [26].
Choreiform movements are another group of symptoms with which children 
can present due to the moyamoya-associated dilated collateral vessels in the basal 
ganglia [27]. Occasionally a characteristic ophthalmologic finding is seen in associa-
tion with MMD identified as “morning glory disk,” an optic disk enlargement with 
concomitant retinovascular anomalies [28].
5. Pathophysiology
In patients with this condition, large intracerebral arteries show a variable degree 
of stenosis and occlusions. Vascular intima shows fibrocellular thickening; elastic 
internal lamina will be tortuous, duplicate or triplicate; and the media show attenua-
tion. Vessels may be dilated and thin-walled or thick-walled and stenosed in different 
regions. The hallmark of MMD is the meshwork of dilated vessels called moyamoya 
vessels (Figure 1). Aneurysms can form in some parts of cerebral vasculature as well.
6. Diagnostic radiology
Diagnosis can be established by invasive and semi-invasive radiological studies. 
At the bedside, transcranial Doppler (TCD) can detect stenosis of major arter-
ies. Conventional CT or MRI helps to detect ischemic and hemorrhagic signs of 
MMD. CT angiography and conventional angiography are important to establish the 
exact point of narrowing in the circle of Willis.
Figure 1. 
Pathophysiology of moyamoya disease (modified from [29]).
5Moyamoya Disease: A Rare Vascular Disease of the CNS
DOI: http://dx.doi.org/10.5772/intechopen.88770
Suzuki and coworkers studied the angiographic progression of MMD and identi-
fied six stages (Table 1) of progression [1, 2].
This staging neither correlates with disease severity nor allows therapeutic risk 
stratification.
6.1 CT head
Cortical and/or subcortical infarction can be seen in the early stages, but in the 
later stages, dilatation of sulci or ventricles due to loss of volume can be seen. In a 
retrospective case series of 32 patients by Kim et al. [30], early stages (stages 1 and 
2 of MMD) had mainly subcortical ischemic changes, whereas later stages (stage 3 
and above) had cortical ischemic changes.
6.2 Magnetic resonance imaging
Diffusion and perfusion MR techniques are superior to CT scan for detection of 
subtle ischemic brain lesions especially in the acute condition. MRI was sensitive to 
detect watershed infarction in 50% of children as per a study done in Canada [31]. 
Dilated collateral vessels at the base of the brain are considered pathognomonic of 
MMD but seen only in some cases. In T2 sequences asymptomatic microbleeds may 
be seen. FLAIR images and T1 sequences may show a characteristic sign called ivy 
sign as in Figure 2 (a linear pattern of increased signal in the leptomeninges and 
perivascular spaces) [33]. This is due to retrograde flow in leptomeninges resem-
bling ivy creeping a stone. Magnetic resonance angiography (MRA) has surpassed 
conventional angiography in some centers as the primary imaging method although 
the latter is still considered as the gold standard.
6.3 Angiography
Conventional cerebral angiography is the gold standard for the diagnosis of MMD 
as it can clearly demonstrate the stenotic vessels in the anterior circulation as well as 
the collateral tuft of vessels formed (Figure 3). Apart from this, the small aneurysms 
which may be associated with MMD also can be detected in cerebral angiography.
Stage Characteristics
Stage 1 • Narrowing of carotid fork only
• Narrowed ICA bifurcation
Stage 2 • Initiation of basal moyamoya
• Dilated ACA, MCA, and narrowed ICA bifurcation with moyamoya change
Stage 3 • Intensification of the “moyamoya”
• Further increase in moyamoya change of the ICA bifurcation and narrowed ACA and MCA 
together with the reduction of flow
Stage 4 • Minimization of moyamoya vessels
• Moyamoya change reducing with occlusive changes in ICA and tenuous ACA and MCA
Stage 5 • Reduction of moyamoya
• Further decrease in moyamoya change with occlusion of ICA, ACA, and MCA (no flow)
Stage 6 • Disappearance of moyamoya vessels
• The cerebral circulation is supplied only by the external carotid system
Table 1. 
Suzuki staging system for moyamoya.
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Figure 2. 
FLAIR sequence showing ivy sign (modified from [32]).
Figure 3. 
Characteristic “puff of smoke” appearance in cerebral angiography.
6.4 Transcranial Doppler (TCD)
Stenosed vessels will have increased flow velocity proportional to the degree of 
stenosis, which can be detected noninvasively by TCD.
6.5 Electro encephalogram (EEG)
A specific pattern of hyperventilation-induced diffuse monophasic slow waves 
called “build-up” and post-hyperventilation “rebuild-up” waves similar to build-up 
waves in patients without MMD may be observed in patients with MMD [34].
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Perfusion CT, xenon-enhanced CT, perfusion-weighted MRI, positron emission 
tomography (PET), and single-photon emission CT (SPECT) with acetazolamide 
challenge are other modalities rarely used in diagnosis [12].
7. Diagnostic criteria for MMD
A Japanese research group has put forward the following diagnostic criteria for 
the diagnosis of MMD [35]:
• Stenosis or occlusion at the terminal portion of the internal carotid artery 
and at the proximal portion of the anterior and middle cerebral arteries 
on  magnetic resonance angiography (MRA).
• Abnormal vascular networks in the basal ganglia on MRA; these networks can 
also be diagnosed by the presence of multiple flow voids on brain MRI.
• Bilateral angiographic findings; although unilateral angiographic findings 
are considered probable.
• Conditions to be excluded:
 ○ Arteriosclerosis
 ○ Autoimmune disease
 ○ Brain neoplasm
 ○ A history of cranial irradiation
 ○ Down syndrome
 ○ Head trauma
 ○ Neurofibromatosis
 ○Meningitis
8. Treatment of MMD
In the acute stage, treatment is symptomatic for those patients with ischemic or 
hemorrhagic stroke as per acceptable guidelines. It should be focused on treating 
elevated intracranial pressure, evacuation of hematoma, draining intraventricular 
hemorrhage by external ventricular drain (EVD), control of seizures, glycemic 
control, and treatment of fever.
In children diagnosed with MMD, crying and hyperventilation should be 
avoided as it can induce cerebral vasoconstriction. Pain management also should be 
taken care of. Supplemental oxygen also helps in avoiding hypoxia. Generally, hypo-
tension, hyperthermia, hypoxia, hypocarbia, and hypovolemia should be avoided.
There are no interventions proved to improve outcome in MMD. The utility 
of thrombolysis has not been studied yet and may be risky due to the possibility 
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of development of hemorrhage from the fragile collateral vessels [36]. Aspirin 
has been recommended by the American College of Chest Physicians (ACCP) for 
children with ischemic stroke [37].
There were no significant differences in outcome between medically and 
surgically treated patients with MMD as per a large survey from Japan, but a later 
review revealed that 38% of 651 patients with MMD who initially underwent 
medical management ultimately had to go for surgery because of progressive 
symptoms [38].
8.1 Secondary stroke prevention
Treatment of underlying diseases like sickle cell disease is helpful in second-
ary prevention. Surgical revascularization is the mainstay of secondary preven-
tion. Antiplatelet medications like aspirin have an important role in preventing 
stroke in mild disease or asymptomatic patients who are at high risk for surgery 
[39]. Oral anticoagulants are not helpful as they can increase the chance of hem-
orrhage. Calcium channel blockers were used in some reports [40]. Endovascular 
embolization has been used for the obliteration of aneurysm associated  
with MMD.
9. Surgical management of moyamoya disease
The aim of surgical management of moyamoya disease is to vascularize and 
restore the blood supply by bypassing the stenosed area. It will stabilize the cere-
brovascular hemodynamics. It prevents bleeding by preventing the progression of 
the thin moyamoya vessels. Improvement and or normalization of cerebral hemo-
dynamics by the surgical intervention will also prevent secondary stroke prevention 
and improve the neurological and neurocognitive outcome.
Revascularization surgery is the most effective treatment for hemorrhagic MMD 
[41] and can be effective in preventing future stroke events in adults [42].
The main indications for the surgical interventions are cerebral hemodynamic 
impairment and repeat ischemic symptoms. The severity of the disease to assign 
a patient for surgical intervention can be made by the Berlin moyamoya grading 
system (Table 2). But the literature has not mentioned the severity at which there is 
an indication for surgical intervention.
Variable Characteristics Points
Digital subtraction 
angiography
Steno-occlusive lesion + moyamoya vessels 1
Steno-occlusive lesion + moyamoya 
vessels + intracranial compensation routes
2
Steno-occlusive lesion + extracranial compensation 
routes
3
MRI No signs of ischemia, hemorrhage, or atrophy 0
Signs of ischemia, hemorrhage, or atrophy 1
Cerebrovascular reserve 
capacity
No steal phenomenon (≥5%) 0
Steal phenomenon (<5%) 2
Table 2. 
The Berlin moyamoya grading [43].
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10. The Berlin moyamoya grading
It incorporates digital subtraction angiography (DSA), MRI, and cerebrovascu-
lar reserve capacity (CVRC) which gives the information of the functional cerebro-
vascular assessment of hemodynamic impairment [43].
It was proposed by Czabanka et al. According to the grading system, there are 
three grades:
1. Grades 1–2: mild
2. Grades 3–4: moderate
3. Grades 5–6: severe
11. Indications for surgical revascularization
Patients with ischemic symptoms and progressive disease with impairment in 
cognition benefit from surgical revascularization methods. It can be achieved by 
direct and indirect methods.
11.1 Direct surgical treatment
A branch of the external carotid artery is connected to the branch of the internal 
carotid artery beyond the stenosis to bypass the stenosed segment. Superficial tempo-
ral artery to middle cerebral artery (STA-MCA) (Figure 4) bypass is the commonly 
used technique [45]. Other less common direct techniques are STA-ACA, STA-PCA, 
and occipital artery-PCA anastomosis. These direct techniques are used when an 
immediate recirculation is indicated. The major drawback is that this cannot be easily 
done in children with MMD because of the smaller size of donor and recipient arteries.
11.2 Indirect surgical treatment
In this technique, a vascularized tissue supplied by the external carotid artery 
(e.g., dura, temporalis muscle, or the superficial temporal artery itself) is placed in 
direct contact with the brain surface, which results in ingrowth of new blood vessels 
to the underlying cerebral cortex (Figure 5). In this technique, good cerebral blood 
flow is established after a few weeks and so not suitable for emergency cases [46], 
but good for pediatric patients with MMD because of the lower technical difficulty. 
The following are the options for indirect revascularization [47]:
• Encephaloduroarteriosynangiosis (EDAS) and its modification called pial 
synangiosis
• Encephalomyosynangiosis (EMS)
• Encephalo-duro-arterio-myosynangiosis (EDAMS)
• Encephaloarteriosynangiosis
• Encephaloduroarteriosynangiosis
• Omental transplantation
Vascular Malformations of the Central Nervous System
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• Craniotomy with inversion of the dura
• Multiple burr holes without vessel synangiosis
• Cervical sympathectomy
Figure 5. 
Indirect bypass procedure of indirect bypass procedure: dissected temporal muscle on the brain surface 
(modified from Acker et al. [44]).
Figure 4. 
Direct bypass procedure of superficial temporal artery (STA) and M3 branches of the middle cerebral artery 
(MCA) (modified from Acker et al. [44]).
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11.3 Combined techniques
Houkin et al. first performed a combined revascularization surgery. It com-
bined the superficial temporal artery and M3 branches of the middle cerebral 
artery (STA-MCA) bypass and encephalo-duro-arterio-myosynangiosis (EDAMS) 
(Figure 6). The aim of the combined procedure is to improve the results to serve as 
an alternative in case the direct bypass fails and prevents second surgery. The direct 
bypass immediately improves the hemodynamics [44]. A 2005 systematic review 
from Japan compared direct, indirect, and combined techniques and found that 
there is no statistically significant difference between all these techniques in terms 
of outcome during 58 months of follow-up period [48]. Efficacy of medical and 
surgical management was also compared in a large survey conducted in Japan and 
concluded that there is no significant difference between the two [49]. However, in 
another study, it was found that children initially underwent medical therapy had to 
ultimately go for revascularization surgery more than the children who underwent 
surgery in the first instance [38].
11.4 The complication of the surgical revascularization
Surgical revascularization is not risk-free. This can range from a transient 
increase in intracranial pressure resulting in headache, seizures, and reversible neu-
rological deficits to perioperative stroke. The mechanism is cerebral hyperperfusion 
syndrome because of the revascularization-induced hyperperfusion of the area 
supplied by the chronically vasoconstricted blood vessels, where the autoregulation 
is impaired. Incidence of this phenomenon was found to be up to 47% [50].
Figure 6. 
Combined revascularization procedure. The temporal muscle is positioned on the brain surface, and the STA is 
a bypass graft to the M3 branch of MCA (modified from Acker et al. [44]).
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All adults and children with ischemic MMD or MMS should have aspirin for 
a long term. If there are no contraindication and significant ischemic symptoms, 
surgical revascularization is a reasonable option [47]. AHA guidelines recommend 
it for patients with compromised cerebrovascular perfusion according to blood flow 
studies [39]. As mentioned before there is no evidence for opting for direct or indi-
rect revascularization or vice versa, though the latter is preferred in the pediatric 
age group. Evidence for postoperative use of aspirin is limited. In a recent retrospec-
tive study, patients treated with postoperative aspirin had better outcome [44, 51].
12. Prognosis
Prognosis depends on how fast the blockage occurs and how effective the col-
lateral circulation is established. Fifty to sixty-six percent of patients will have the 
progression of the disease, and they have a poor outcome. Pediatric patients who 
were surgically treated were found to have disease progression in an estimated 2.6% 
of patients only. Among untreated asymptomatic patients, the annual stroke rate 
was found to be 3.2% and disease progression in 80% [52, 53].
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
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